Earnings Call Summary | BIOSYENT INC(BIOYF.US) Q4 2023 Earnings Conference
Earnings Call Summary | BIOSYENT INC(BIOYF.US) Q4 2023 Earnings Conference
The following is a summary of the BioSyent Inc. (BIOYF) Q4 2023 Earnings Call Transcript:
以下是BioSyent Inc.（BIOYF）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BioSyent reports Q4 sales around $8.3 million, marking an 11% increase from the previous year. Full-year sales reached approximately $32 million, up 13% year-on-year.
Earnings per share for Q4 stand at $0.12, up from the previous year's $0.09. Full-year earnings per share saw an increase of over 20%, settling at $0.53.
BioSyent報告稱，第四季度銷售額約爲830萬美元，比上年增長11％。全年銷售額達到約3200萬美元，同比增長13％。
第四季度的每股收益爲0.12美元，高於去年的0.09美元。全年每股收益增長了20％以上，收於0.53美元。
Business Progress:
業務進展：
The company launched Gelclair and partnered with the Canadian Menopause Society for menopauseinformation.ca in Q4.
BioSyent continued to return profits to shareholders with an increase in the shareholder dividend and purchase of over 93,000 shares under the regular course issuer bid (NCIB).
Plans to discover fresh revenue-generating assets are in the works with ongoing discussions of acquisition and product licensing opportunities.
該公司在第四季度推出了Gelclair，並與加拿大更年期協會合作開發了menopauseinformation.ca。
BioSyent繼續向股東返還利潤，增加了股東分紅，並根據常規股票發行人的出價（NCIB）購買了超過93,000股股票。
發掘新的創收資產的計劃正在制定中，有關收購和產品許可機會的討論仍在進行中。
More details: BIOSYENT INC IR
更多詳情： BIOSYENT INC
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。